India’s Vaccination Drive

Why in News: India launched the Zero Measles-Rubella Elimination Campaign (2025) after receiving the Measles & Rubella Champion Award (2024).

Achievements

  • Largest immunisation programme: UIP covers 2.6 crore infants and 2.9 crore pregnant women annually.
  • Mortality reduction: Under-5 mortality declined from 45 to 31 per 1,000 live births (2014–21).
  • Expanded coverage: Six new vaccines added in the last decade.
  • Mission Indradhanush (MI): Raised full coverage from 62% to over 75% (2020s), strengthened by Intensified MI.
  • Community outreach: Gram Swaraj Abhiyan integrated into campaigns; 12 MI/IMI phases vaccinated 5.46 crore children and 1.32 crore pregnant women.
  • Global recognition: India received Measles & Rubella Champion Award (2024).

Key Lessons

1. Policy Innovation: Micro-planning and targeted interventions bridge gaps.

2. Tech Integration: U-WIN, eVIN, SAFE-VAC ensure digital tracking and transparency.

3. Resilience in Crisis: IMI 5.0 and Zero Measles-Rubella Campaign overcame COVID-19 setbacks.

4. Domestic Manufacturing: COVID-19 vaccination showcased “Make in India” capacity and Vaccine Maitri diplomacy.

5. Public-Private Partnerships: Strengthened R&D and supply chains.

6. Surveillance Linkages: Polio lessons improved monitoring of vaccine-preventable diseases.

Way Forward

  • Reach the unreached: Mobile vaccination teams for migratory and remote populations.
  • Community engagement: Strengthen IEC campaigns, leverage local influencers to tackle vaccine hesitancy.
  • Digital strengthening: Ensure interoperability of U-WIN with state health systems.
  • Equity focus: Prioritise vulnerable groups (urban slums, tribal belts).
  • Cold chain expansion: Invest in last-mile solar-based and AI-enabled cold storage.
  • Private sector integration: Engage private clinics/pharmacies in routine immunisation.
  • Global leadership: Position India as a hub for affordable vaccines under Gavi/WHO platforms.
  • One Health lens: Link immunisation with zoonotic and environmental surveillance.

GS Paper III (Science & Tech, Health): Vaccine innovation, cold chain management, pandemic preparedness, Make in India in pharma.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top